Phase 2 N=36 A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
Priapism
Primary: Percent Change in Priapic Events From Baseline to 26 Weeks — -61.3 Percent change from baseline — p=0.0676
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=240 Comparing the Effects of Oral Contraceptive Pills Versus Metformin
PCOS
Primary: Number of Participants With Metabolic Syndrome After 6 Months of Treatment Metformin or OCP+Metformin for 6 Months. — 17; 17; 18 Participants
N/A N=50 Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training
Schizophrenia · Schizo Affective Disorder · Social Skills
Primary: Change in Social Attention: Social Engagement Latency (SEL) — -195 milliseconds — p=0.004
N/A N=206 LORA-PITA IV General Investigation
Status Epilepticus
Primary: Number of the Participants With Adverse Drug Reactions — 7 Participants
N/A N=154 Mindfulness Oriented Recovery Enhancement for Chronic Pain and Opioid Relapse
Opioid Use · Chronic Pain
Primary: Drug Relapse Through 16-weeks. — 39; 44 Participants — p=.02
Phase 4 N=57 Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)
Major Depressive Disorder
Primary: Change in Montgomery Asberg Depression Rating Scale Score — 18; 2; 3; 8 persons with positive treatment response
N/A N=18 Determining Learning Ability in People With Aphasia
Aphasia
Primary: SRT Observational Learning Ability — -0.03 Cohen's d
Phase 1 N=69 An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Neoplasms
Primary: Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 1; 1; 1 Participants
Phase 2 N=235 Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
Atopic Dermatitis · Skin Diseases
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 — -55.1; -52.2; -61.4; -50.4 percent change — p=0.505
Phase 4 N=527 Zoster Eye Disease Study
Herpes Zoster Ophthalmicus
Primary: Number of Participants With the First Occurrence of New or Worsening Stromal Keratitis Without Ulceration (SK), Endothelial Keratitis (EK), Iritis (IR), Dendriform…
N/A N=139 Effect of Nasal Positive Airway Pressure Versus Standard Care on Oxygenation and Ventilation During Propofol-based Sedation for Colonoscopy in Patients With High Risk of Airway Obstruction
Obstructive Sleep Apnea, Obesity
Primary: Time Taken From Initiation of Induction to the First Airway Intervention — 5; 10 minutes
N/A N=50 Clinical Study for the Evaluation of the Effectiveness of Use of a Poly-L Lactic Acid Injectable Filler for the Aesthetic Treatment of Buttocks Volume Depression
Buttocks Volume Loss
Primary: Change From Baseline in Buttocks Volume 6 Months After Treatment — 22.21 cm^3 — p=<0.0001
N/A N=95 Neuroplasticity in Parkinson´s Disease After Training
Parkinson Disease · Physical Activity · Gait Disorders, Neurologic
Primary: Mini-BESTest — 20.7; 21.0; 22.1; 21.8 score on a scale — p=0.57
Phase 2 N=34 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Biphenotypic Acute Leukemia
Primary: Disease Free Survival — 70.6 percentage of participants — p=0.002
N/A N=40 Community Health Worker And MHealth to ImProve Viral Suppression (CHAMPS Pilot)
HIV/AIDS
Primary: Viral Load — 15; 11; 2; 1 Participants